PCV50 COSTS OF MAJOR BLEEDS IN ACUTE CORONARY SYNDROME PATIENTS  by Brown, R et al.
PCV50
COSTS OF MAJOR BLEEDS IN ACUTE CORONARY
SYNDROME PATIENTS
Brown R1, Ferrari E2, Drogoul L2, Nachit-Ouinekh F3, De Cock E4
1United BioSource Corporation, London, London, UK,
2Hopital Pasteur, Nice, France, 3GlaxoSmithKline, Paris, France,
4United BioSource Corporation, Barcelona, Spain
OBJECTIVES: Major bleeding in acute coronary syndrome
(ACS) patients has a signiﬁcant impact on clinical outcomes. The
economic costs associated with these events have not been
assessed. This study was undertaken to estimate the costs asso-
ciated with manage major bleeds in ACS patients in the hospital
setting METHODS: A retrospective chart review was undertaken
in a French hospital to identify ACS patients with the following
bleeding events: intracranial haemorrhage (ICH), retroperitoneal
(RP) gastrointestinal (GI), puncture site or excessive surgical
bleeds (PSB), blood transfusion requiring 2 or more units, or
decrease in Hb > 3g/dL (DHb). Patient age, reason for admission,
extended length of stay (LOS) attributed to the bleed, ward type,
and resources to manage the bleed were collected. RESULTS: 48
cases were analysed, 52% were males, with an average age of
72.5 years. The reasons for hospital admission were 39.6% non
ST-segment Elevation Myocardial Infarction (NSTEMI), 43.8%
ST-segment Elevation MI (STEMI) and 10.4% unstable angina
(UA). The distribution of hemorrhagic events were 40.4% DHb,
27.7% transfusions, 21% PSB, 8.5% GI and 2.1% RP bleeds.
The mean length of stay (LOS) was 8.5 days across all patients.
Extended 6.5 day mean LOS (76% of total stay) was found for
20 patients. The number of extra days varied by type of bleed.
80% of PSB patients had extended stays compared to 50% of GI
bleed, 38% of transfusion and 21% DHb patients. Ultrasound
was the most common additional procedure followed by endos-
copy. Applying unit costs from France for procedures, transfu-
sions, and extended LOS resulted in additional costs of €1709 for
DHb, €3245 for transfusions, €2116 for GI, €4091 for RT and
€6585 for PSB. CONCLUSION: Hospitalised ACS patients with
bleeding complications have increased mean resource use and
41% have extended LOS leading to an estimated additional
average €3185 for the hospital stay.
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OBJECTIVES: The Norwegian Government changed the reim-
bursement criteria for statins June 1, 2005. Simvastatin was
deemed ﬁrst-line statin except when otherwise medically justi-
ﬁed. Further, eligible treated patients were to be switched from
atorvastatin to simvastatin within one year, with recommenda-
tions to double the mg dose. The objective of this analysis was
to estimate the: 1) impact of statin on lipid control and CV
events, and 2) cost effectiveness of non-switching vs switching
in statin therapy. METHODS: Prescription data were obtained
from a Norwegian Institute of Public Health report of national
pharmacy prescription registry data. Average reduction in total
cholesterol was estimated based on dose distribution of atorv-
astatin pre-switch and simvastatin post-switch according to
product labeling. CV events, costs, and QALYs were estimated
from a lifetime Markov model applying Framingham risk
equations and Norwegian epidemiologic data, assuming a
primary prevention population. Event costs were based on
Norway DRG costs; drug costs on current and future treatment
costs, assuming two years to generic atorvastatin. Discounting
was 3% per annum. RESULTS: Following June 1, 2005,
50,616 patients were identiﬁed who switched from atorvastatin
to simvastatin; 38% to a lower potency dose. Dose distribution
for atorvastatin was 40.4%/44.4%/12.6%/2.5% for 10/20/40/
80 mg, respectively. Post-switch simvastatin distribution was
9.4%/45.4%/39.9%/5.2% for 10/20/40/80 mg, with an esti-
mated 8.6% absolute loss in total cholesterol reduction. This
could lead to 30 additional CV events per 1000 patients, and
0.12 QALYs lost. The incremental cost effectiveness ratio for
non-switching versus the switching policy is estimated to be
€8526 per QALY saved. CONCLUSION: Following the policy
in Norway, a considerable portion of patients were switched to
a simvastatin dose with lower cholesterol lowering effect and a
consequent increased CV risk. Maintaining patients on estab-
lished statin therapy may have been a more cost-effective
approach in this setting.
PCV52
ATTITUDES AND BELIEFS OF PHYSICIANS ABOUT
HYPERCHOLESTEROLEMIA IN SPAIN:THE PRACTICE STUDY
Nocea G1,Troya J2, Garcia E3, Gimenez G4, Marcos G5, Caloto MT6,
Alemao E7, Suarez C8
1MSD Spain, Madrid, Spain, 2H.Virgen de la Salud,Toledo, Spain,
3Consultorio El Carpio, Cordoba, Spain, 4H. Parc Tauli, Barcelona,
Spain, 5H. San Pedro de Alcantara, Caceres, Spain, 6Merck, Sharp &
Dohme, Madrid, Spain, 7Merck & Co,Whitehouse Station, NJ, USA,
8H. de La Princesa, Madrid, Spain
OBJECTIVES: To assess the attitudes and beliefs of physi-
cians about hypercholesterolemia and its treatment in Spain.
METHODS: An observational, cross-sectional questionnaire
survey was performed in 2006. 22 cardiologists, 23 endocri-
nologists, 22 internists and 21 primary care physicians were
included. Their attitudes and beliefs about hypercholester-
olemia and its treatment were assessed by means of 7-items
Likert scales and ordinal categorical variables. RESULTS:
Eighty-eight physicians were included in the study, 77% were
over 40 years of age and mainly working in urban areas (82%).
A total of 97.7% agreed that national guidelines and target
levels for LDL-c management are clear, and 11.5% considered
they are difﬁcult to apply due to the frequent changes in the
LDL-c target level. A total of 48.2% agreed that statin mono-
therapy is sufﬁcient to make most of patients get to LDL-c goal
and, for patients not reaching LDL-c goal, 82.7% agreed they
would consider trying a combination therapy, 81% increasing
the statin dose, and 21.7% switching to another statin. When
they were asked to state the most frequent reason that made
patients with lipid-lowering therapy not getting to cholesterol
goal, 60.2% referred to the patient’s lack of compliance,
35.2% to the lack of compliance with diet/exercise, and 31.8%
to the insufﬁcient dose or efﬁcacy of pharmacologic therapy. A
total of 63.2% agreed that compliance is reduced because
patients take too many drugs, and 97.7% agreed that ﬁxed
dose of combination therapies would increase patient compli-
ance. CONCLUSION: Despite the high degree of knowledge
about the recommendations for LDL-c target levels among phy-
sicians and the limited additional efﬁcacy obtained by titrating
the statin dose, over half of physicians believe that statin mono-
therapy is enough to achieve LDL-c target levels, and mainly
attribute to the patient’s lack of compliance the low proportion
of patients achieving LDL-c target levels.
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